SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
A Phase 2 open-label, single-arm, non-randomized study in the treatment of advanced
hepatocellular carcinoma (HCC) patients who failed prior treatment with sorafenib using a
Simon's 2-stage design. A set minimum number of patients must demonstrate disease control at
16 weeks to proceed to Stage 2. At Stage 2, a set number of patients must have disease
control at 16 weeks to declare that SGI-110 is of interest in the treatment of advanced HCC
after failure of prior sorafenib.